InterVenn BioSciences Corp (InterVenn) is a biotechnology company that focuses on advancing personalized medicine by decoding the human glycoproteome. InterVenn’s lead product GlycoVision, is an artificial intelligence and machine learning biomarker discovery platform that provides a high-resolution view into an untapped layer of biology. The company collaborates with pharmaceutical, biotechnology, and diagnostic companies to accelerate disease insights and improve drug development. InterVenn BioSciences is headquartered in South San Francisco, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company InterVenn BioSciences
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
- InterVenn BioSciences Company Overview
- InterVenn BioSciences Company Snapshot
- InterVenn BioSciences Pipeline Products and Ongoing Clinical Trials Overview
- InterVenn BioSciences - Pipeline Analysis Overview
- InterVenn BioSciences - Key Facts
- InterVenn BioSciences - Major Products and Services
- InterVenn BioSciences Pipeline Products by Development Stage
- InterVenn BioSciences Pipeline Products Overview
- Blood-Based Diagnostic Test - Advanced Adenoma
- Blood-Based Diagnostic Test - Advanced Adenoma Product Overview
- Blood-Based Diagnostic Test - Hepatocellular Carcinoma
- Blood-Based Diagnostic Test - Hepatocellular Carcinoma Product Overview
- Blood-Based Diagnostic Test - Nasopharyngeal Carcinoma
- Blood-Based Diagnostic Test - Nasopharyngeal Carcinoma Product Overview
- Blood-Based Diagnostic Test - Non-Alcoholic SteatoHepatitis
- Blood-Based Diagnostic Test - Non-Alcoholic SteatoHepatitis Product Overview
- Blood-Based Diagnostic Test - Non-Small Cell Lung Cancer
- Blood-Based Diagnostic Test - Non-Small Cell Lung Cancer Product Overview
- Blood-Based Diagnostic Test - Pancreatic Cancer
- Blood-Based Diagnostic Test - Pancreatic Cancer Product Overview
- Blood-Based Diagnostic Test - Prostate Cancer
- Blood-Based Diagnostic Test - Prostate Cancer Product Overview
- Blood-Based Diagnostic Test - Renal Cell Carcinoma
- Blood-Based Diagnostic Test - Renal Cell Carcinoma Product Overview
- Dawn - Lung Cancer
- Dawn - Lung Cancer Product Overview
- Dawn - Pancreatic Cancer
- Dawn - Pancreatic Cancer Product Overview
- Dawn IO Melanoma
- Dawn IO Melanoma Product Overview
- Diagnostic Test - Bone Cancer
- Diagnostic Test - Bone Cancer Product Overview
- Diagnostic Test - Soft Tissue Sarcoma
- Diagnostic Test - Soft Tissue Sarcoma Product Overview
- Glori
- Glori Product Overview
- GlycoKnow Colon
- GlycoKnow Colon Product Overview
- Immuno-Therapy Response Prediction Test - NSCLC
- Immuno-Therapy Response Prediction Test - NSCLC Product Overview
- Treatment Monitoring Panel - Autoimmune Diseases
- Treatment Monitoring Panel - Autoimmune Diseases Product Overview
- Treatment Monitoring Panel - Infectious Disease
- Treatment Monitoring Panel - Infectious Disease Product Overview
- Treatment Monitoring Panel - Inflammation
- Treatment Monitoring Panel - Inflammation Product Overview
- InterVenn BioSciences - Key Competitors
- InterVenn BioSciences - Key Employees
- InterVenn BioSciences - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- InterVenn BioSciences, Recent Developments
- Oct 13, 2023: InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association
- Sep 27, 2023: InterVenn Biosciences Welcomes Accomplished Diagnostics Executive Joshua Stahl as CEO
- Apr 19, 2023: InterVenn Biosciences to present clinical data on circulating serum glycoproteins for unprecedented pre-cancer detection as “poster of distinction” at Digestive Disease Week 2023
- Oct 26, 2022: Erwin Estigarribia is Appointed President and Chief Operating Officer of InterVenn Biosciences
- Oct 04, 2022: InterVenn Biosciences Expands Board of Directors with Dr. Jason Myers and Carol Berry to Support Next Phase of Growth
- Sep 09, 2022: InterVenn Biosciences to Present at the 20th Annual Morgan Stanley Global Healthcare Conference
- Sep 06, 2022: InterVenn Biosciences to present at the 20th Annual Morgan Stanley Global Healthcare Conference
- Jun 02, 2022: Intervenn Biosciences announces new data validating the clinical performance of DAWN IO Melanoma as a novel liquid biopsy test to improve assessment of benefit to cancer patients
- Jun 01, 2022: InterVenn Biosciences joins the WIN and FNIH Biomarker Consortiums to introduce a Glycoproteomic Option for Liquid Biopsies
- May 06, 2022: InterVenn to present new clinical data at ASCO 2022 on using Glycoproteomics as powerful liquid biopsy tests for early detection of cancer and prediction of checkpoint inhibitor treatment benefit
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- InterVenn BioSciences Pipeline Products and Ongoing Clinical Trials Overview
- InterVenn BioSciences Pipeline Products by Equipment Type
- InterVenn BioSciences Pipeline Products by Indication
- InterVenn BioSciences, Key Facts
- InterVenn BioSciences, Major Products and Services
- InterVenn BioSciences Number of Pipeline Products by Development Stage
- InterVenn BioSciences Pipeline Products Summary by Development Stage
- Blood-Based Diagnostic Test - Advanced Adenoma - Product Status
- Blood-Based Diagnostic Test - Advanced Adenoma - Product Description
- Blood-Based Diagnostic Test - Hepatocellular Carcinoma - Product Status
- Blood-Based Diagnostic Test - Hepatocellular Carcinoma - Product Description
- Blood-Based Diagnostic Test - Nasopharyngeal Carcinoma - Product Status
- Blood-Based Diagnostic Test - Nasopharyngeal Carcinoma - Product Description
- Blood-Based Diagnostic Test - Non-Alcoholic SteatoHepatitis - Product Status
- Blood-Based Diagnostic Test - Non-Alcoholic SteatoHepatitis - Product Description
- Blood-Based Diagnostic Test - Non-Small Cell Lung Cancer - Product Status
- Blood-Based Diagnostic Test - Non-Small Cell Lung Cancer - Product Description
- Blood-Based Diagnostic Test - Pancreatic Cancer - Product Status
- Blood-Based Diagnostic Test - Pancreatic Cancer - Product Description
- Blood-Based Diagnostic Test - Prostate Cancer - Product Status
- Blood-Based Diagnostic Test - Prostate Cancer - Product Description
- Blood-Based Diagnostic Test - Renal Cell Carcinoma - Product Status
- Blood-Based Diagnostic Test - Renal Cell Carcinoma - Product Description
- Dawn - Lung Cancer - Product Status
- Dawn - Lung Cancer - Product Description
- Dawn - Pancreatic Cancer - Product Status
- Dawn - Pancreatic Cancer - Product Description
- Dawn IO Melanoma - Product Status
- Dawn IO Melanoma - Product Description
- Diagnostic Test - Bone Cancer - Product Status
- Diagnostic Test - Bone Cancer - Product Description
- Diagnostic Test - Soft Tissue Sarcoma - Product Status
- Diagnostic Test - Soft Tissue Sarcoma - Product Description
- Glori - Product Status
- Glori - Product Description
- GlycoKnow Colon - Product Status
- GlycoKnow Colon - Product Description
- Immuno-Therapy Response Prediction Test - NSCLC - Product Status
- Immuno-Therapy Response Prediction Test - NSCLC - Product Description
- Treatment Monitoring Panel - Autoimmune Diseases - Product Status
- Treatment Monitoring Panel - Autoimmune Diseases - Product Description
- Treatment Monitoring Panel - Infectious Disease - Product Status
- Treatment Monitoring Panel - Infectious Disease - Product Description
- Treatment Monitoring Panel - Inflammation - Product Status
- Treatment Monitoring Panel - Inflammation - Product Description
- InterVenn BioSciences, Key Employees
- InterVenn BioSciences, Other Locations
- Glossary
- InterVenn BioSciences Pipeline Products by Equipment Type
- InterVenn BioSciences Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Cisbio US Inc
- Medisystems Corporation
- QuanDx, Inc.
- Lifespex Inc.
